Anzeige
Mehr »
Login
Dienstag, 18.03.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Spektakuläre News bei dieser Aktie - ist das ist die Chance des Jahres?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40E1B | ISIN: US47010C8055 | Ticker-Symbol: 1JA
NASDAQ
17.03.25
19:25 Uhr
0,464 US-Dollar
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
JAGUAR HEALTH INC Chart 1 Jahr
5-Tage-Chart
JAGUAR HEALTH INC 5-Tage-Chart

Aktuelle News zur JAGUAR HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:00Jaguar Health falls as it announces reverse stock split2
JAGUAR HEALTH Aktie jetzt für 0€ handeln
13:54Jaguar Health initiates reverse stock split to meet Nasdaq standards2
13:46Jaguar Health leitet Aktienzusammenlegung ein, um NASDAQ-Standards zu erfüllen1
13:38Jaguar Health, Inc. Announces Reverse Stock Split131Reverse split approved at March 2025 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 SAN FRANCISCO, CA / ACCESS Newswire...
► Artikel lesen
DoJaguar Health, Inc. - 8-K, Current Report9
DoJaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders1.305Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion diseaseFDA...
► Artikel lesen
27.02.Jaguar Health, Inc.: Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value665Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion diseaseFDA...
► Artikel lesen
27.02.Jaguar Health, Inc. - 8-A12B, Registration of securities4
20.02.Jaguar Health, Inc. - 8-K, Current Report10
19.02.Jaguar Health, Inc.: Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure287This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications...
► Artikel lesen
18.02.Jaguar Health advances cholera treatment, eyes FDA voucher7
18.02.Jaguar Health, Inc.: Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300213Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related...
► Artikel lesen
13.02.Jaguar Health, Inc.: Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts330SAN FRANCISCO, CA / ACCESS Newswire / February 13, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Tuesday...
► Artikel lesen
06.02.Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference379Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as...
► Artikel lesen
03.02.Jaguar Health, Inc.: Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025294Trial taking place at Sheikh Khalifa Medical City, a flagship United Arab Emirates hospital and largest teaching medical center in Abu DhabiCrofelemer, Jaguar's novel plant-based prescription drug,...
► Artikel lesen
29.01.Jaguar Health, Inc.: Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO337Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported...
► Artikel lesen
22.01.Jaguar Health, Inc.: Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease , with Proof-of-Concept Data Potentially Available H1 2025294Trial taking place at Sheikh Khalifa Medical City, a flagship tertiary hospital in the United Arab EmiratesPOC data generated from this study could potentially lead to reimbursed early patient access...
► Artikel lesen
10.01.Jaguar Health, Inc.: Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635453SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted...
► Artikel lesen
08.01.Jaguar Health, Inc.: Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase333SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside...
► Artikel lesen
07.01.Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum384Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications...
► Artikel lesen
Seite:  Weiter >>
95 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1